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Abstract
Background: Abnormalities of tubulin polymerization and microtubule assembly are often seen in cancer, which
make them very suitable targets for the development of therapeutic approach against rapidly dividing and
aggressive cancer cells. CYT997 is a novel microtubule-disrupting agent with anticancer activity in multiple cancer
types including prostate cancer. However, the molecular mechanisms of action of CYT997 in prostate cancer have
not been well characterized.
Methods: Src knockdown cells were achieved by lentiviral-mediated interference. The drug effects on cell
proliferation were measured by MTS. The drug effects on cell viability and death were determined by Cell Titer-Glo®
Luminescent cell viability kit and flow cytometry with Zombie Aqua™ staining. The drug effects on apoptosis were
assessed by Cell Death Detection Elisa kit and Western blot with a cleaved PARP antibody. The drug effects on cell
invasion were examined by Matrigel-coated Boyden chambers. Oxidative stress was detected by DCFH-DA staining
and electrochemical biosensor. Mouse models generated by subcutaneous or intracardiac injection were used to
investigate the in vivo drug efficacy in tumor growth and metastasis.
Results: CYT997 effectively inhibited proliferation, survival, and invasion of prostate cancer cells via blocking
multiple oncogenic signaling cascades but not the Src pathway. Inhibition of Src expression by small hairpin RNA
or inactivation of Src by dasatinib increased the CYT997-induced cytotoxicity of in vitro. Moreover, the combination
of dasatinib and CYT997 exhibited a superior inhibitory effect on tumor growth and metastasis compared with
either of the drugs alone.
Conclusion: Our findings demonstrate that blockage of Src augments the anticancer effect of CYT997 on prostate
cancer and suggest that co-treatment of dasatinib and CYT997 may represent an effective therapeutic regimen for
limiting prostate cancer.
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Background
Prostate cancer, known as carcinoma of the prostate, is
the most commonly diagnosed solid tumor among men.
Despite new technology has enabled medical researchers
to develop more reliable, less invasive screening and
treatment methods, prostate cancer still remains the sec-
ond leading cause of cancer-related death in male [1].
The failure of clinical treatment in patients with prostate
cancer is often due to the heterogeneous nature of the
disease. Comparative understanding of genetic pathways
involved in the development and progression of prostate
cancer may help define novel therapeutic targets or/and
identify treatment regimens that are very likely to pro-
vide therapeutic benefit to patients.
Disrupting normal function of microtubules can en-
gage the spindle checkpoint and arrest cell cycle pro-
gression at mitosis, leading to cell death [2]. Therefore,
targeting microtubules is one of the efficient strategies
for cancer treatment. A bunch of clinical chemo drugs,
such as vinblastine, docetaxel, and paclitaxel, have
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potential to suppress microtubule dynamics without af-
fecting microtubule polymer mass [2–4]. Although these
microtubule-targeting agents (MTAs) are widely used to
treat different types of human cancers [5–7], substantial
drawbacks such as narrow therapeutic windows and lack
of oral bioavailability still remain [8]. Moreover, the po-
tential side effects (e.g., neural toxicity) and cardio-
vascular events (e.g., thromboembolism) largely limit
therapeutic efficacy of MTA as single agents against can-
cer. To overcome these clinical problems, many research
efforts have concentrated on developing novel MTAs.
CYT997 is a new microtubule-disrupting agent screened
from Cytopia’s small molecule library, which has been
proven to possess varying degrees of activity against can-
cers through inhibiting tubulin polymerization and dis-
rupting cellular microtubules [9–11]. In phase I clinical
trials, the safety, efficacy, and pharmacokinetics of
CYT997 in cancer patients have been investigated [9].
Src, a non-receptor tyrosine kinase, has been impli-
cated in a variety of different cancer types as well as in
progression to malignancy [12–14]. Activation of Src is
associated with its translocation to the plasma mem-
brane in which Src interacts with a number of important
effectors in response to extracellular signals. Regardless
of which mechanism for Src activation, Src promotes
numerous properties associated with metastatic potential
once it is phosphorylated on tyrosine residues [12, 13]. It
has been reported that Src trafficking requires both
microtubules and actin polymerization [15], which
may link Src functions to MTAs. In hormone-
dependent cancers (e.g., breast and prostate cancer),
steroid hormones trigger association of the androgen
receptor (AR)-estradiol receptor (ER) complex with
Src. A synthetic 10 amino-acid peptide that mimics
the sequence of the SH3 domain-mediated binding of
Src can prevent the AR/ER complex from associating
with Src and inhibit the growth of LNCaP xenografts
established in nude mice [16]. A study from Dr.
Migliaccio’s group shows that targeting the AR do-
main involved in AR/Src association impairs EGF sig-
naling in human fibrosarcoma HT1080 cells [17].
Preclinical studies also established a role of Src in
progressive stages of prostate cancer and cross talk
between Src and AR signaling [18]. AR can also acti-
vate MAP kinase (MAPK) through an early and a late
response pathway in a cell type-dependent manner
[19]. The combination of the Src inhibitor PP2 and
antiandrogen Casodex does not further decrease the
invasion of the LNCaP derivative C4-2 cells [20], sug-
gesting that Src-assisted invasion may involve nonge-
nomic AR actions whereby MAPK axis stimulation by
AR signaling. Recent studies further reported that the
Src inhibitors (e.g., dasatinib, saracatinib, and bosuti-
nib) can inhibit motility, migration, and invasion of
androgen-dependent and androgen-independent prostate
cancer cells in a dose-dependent manner [21, 22].
In this study, we show that CYT997 effectively inhibits
proliferation, viability, and invasion of prostate cancer
cells. Genetic or pharmacological blockage of Src sensi-
tizes prostate cancer cells towards CYT997 regardless of
AR expression. Synergistic treatment with CYT997 and
the Src inhibitor dasatinib exhibits a superior anticancer
effect in mouse models of prostate cancer. These find-
ings provide a molecular and cellular basis for CYT997
treatment, suggesting a clinical evaluation of CYT997 in
combination with dasatinib for the treatment of patients
with prostate cancer.
Methods
Cell lines, reagents, antibodies, and standard assays
Prostate cancer cell lines PC3, DU145, LNCaP, and
22Rv1 were obtained from ATCC and passage <5 were
used in this study. LNCaP-derivative C4-2 and C4-2B
cells were a gift from Dr. Daqing Wu (Georgia Cancer
Center). All cells were maintained in Dulbecco’s modi-
fied Eagle’s medium (DMEM) containing 10% fetal bo-
vine serum (FBS). Luciferase stable PC3 cells were
generated by transduction of pGL4.5 vector (Promoga,
Madison, WI) encoding the luciferase reporter gene luc2
and selection of hygromycin. pLKO.1 lentiviral vectors
harboring small hairpin RNAs (shRNAs) targeting Src
were obtained from Open Biosystems (Huntsville, AL).
CYT997 and dasatinib were purchased from Selleck-
chem (Houston, TX). 2′,7′-Dichlorodihydrofluorescein
diacetate (DCFH-DA) and D-Luciferin bioluminescent
substrate were purchased from Sigma-Aldrich (St Louis,
MO). Antibodies that recognize p62, p-AKT (Ser473), p-
ERK1/2 (Thr202/Tyr204), p-STAT3 (Tyr705), p-Src
(Tyr416), AKT, ERK1/2, STAT3, Src, LC3B I/II, and
cleaved (c)-PARP were purchased from Cell Signaling
Technology (Beverly, MA). β-Actin and Ki67 antibodies
were purchased from Sigma-Aldrich (St Louis, MO) and
Abcam (Cambridge, MA), respectively. Western blot,
cell proliferation, and electrochemical detection were
carried out as described previously [23–28]. Matrigel in-
vasion assays were performed by transwells from BD
biosciences (San Jose, CA) as described previously [23–
26]. Briefly, 5 × 104 serum-starved cells were seeded into
Matrigel-coated Boyden chambers in the presence or ab-
sence of the indicated concentrations of CYT997, and
DMSO containing 10% FBS was added to the lower
chamber. After 24-h treatment, the membranes that
contained invading cells were fixed in methanol and
stained with 0.2% Crystal violet. The dye was dissolved
in 10% acetic acid and read colorimetrically at 590 nm
for quantification of invasion. Cell viability was deter-
mined by CellTiter-Glo® Luminescent cell viability assay
(Promega, Madison, MI) and Zombie Aqua™ fixable
Teng et al. Journal of Hematology & Oncology  (2017) 10:118 Page 2 of 10
viability kit (BioLegend, San Diego, CA). Flow cytometry
data were analyzed using FlowJo software (Tree Star,
Ashland, OR).
Detection of apoptosis
The Cell Death Detection Elisa kit (Roche, Indianapolis,
IN) was used to determine apoptosis by measuring
mono- and oligonucleosomes in the lysates of apoptotic
cells according to the manufacturer’s protocol. Briefly,
the cells treated with different drugs were lysed and
placed into a streptavidin-coated microplate and incu-
bated with a mixture of anti-histone-biotin and anti-
DNA-peroxidase. The amount of peroxidase retained in
the immunocomplex was photometrically determined
with 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulphonic
acid) (ABTS) as the substrate. Absorbance was measured
at 405 nm (492 nm as reference wavelength).
Animal models
Six-week-old male NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/
SzJ) mice were purchased from the Jackson Laboratory
(Bar Harbor, ME), and all animal experiments were ap-
proved by the Institutional Animal Care and Use Com-
mittee (IACUC) of Augusta University. To generate a
xenotransplantation model, exponentially growing PC3
cells (1 × 106 cells) were suspended in 100 μl PBS/matri-
gel (1:1) and injected subcutaneously into the right
flanks of NSG mice. To generate an intracardiac model,
NSG mice were injected via intracardiac with 1 × 106
luciferase-containing PC3 cells.
Drug administration and immunohistochemistry
Four days after PC3 cell implantation, mice were ran-
domized to receive control vehicle and drug(s) (n = 5).
The treatment groups received followed equal volume
treatment of CYT997 (20 mg/kg), dasatinib (10 mg/kg),
or in combination of CYT997 (20 mg/kg) and dasatinib
(10 mg/kg), respectively. CYT997 was administered by
garage twice per day for a total of 3 weeks, and dasatinib
was intraperitoneally (i.p.) administered 5 days per week
for a total of 4 weeks. The control mice were injected
i.p. with 100 μl sterile saline. Tumor growth was mea-
sured externally every 4 to 7 days using vernier calipers
as length × width2 × 0.52. The mice were sacrificed on
treatment day 42, and the lungs were removed and proc-
essed for immunohistochemistry (IHC) with Ki67 anti-
body and pathological analysis by HE staining as
described previously [29, 30]. For intracardiac models,
mice were randomized for vehicle (sterile saline) or
combined (20 mg/kg CYT997 with 10 mg/kg dasatinib)
treatment. Mice were imaged for luciferase signal by an
intraperitoneal injection of luciferin (15 μg in 100 μl
PBS) every other week for 4 weeks using a Xenogen
IVIS-200 In Vivo Imaging System (PerkinElmer, Wal-
tham, MA).
Statistical analysis
Treatment effects were evaluated using a two-tailed Stu-
dent t test at each measurement time point. To assess
the longitudinal effect of treatment, a mixed model was
employed to test the overall difference across all groups
as well as between each pair of groups during the whole
study period. The data were presented as means ± SD
from three or more independent experiments, and a p
value less than 0.05 was considered significant.
Results
CYT997 inhibits proliferation, viability, and invasion of
prostate cancer cells through blocking multiple signaling
pathways
CYT997 has been tested against a panel of 16 cancer cell
lines and displays broad cytotoxicity in vitro [10]. To
evaluate the drug effects on prostate cancer, prostate
cancer cell lines with different genetic background were
treated with various concentrations of CYT997. AR are
highly expressed in 22Rv1, LNCaP, and its derivatives
(C4-2 and C4-2B), and they are androgen-responsive cell
lines. In contrast, DU145 and PC3 have relatively low
basal levels of AR which are unresponsive to androgen
stimulation. CYT997 inhibited proliferation and viability
of all these cells in a dose-dependent manner (Fig. 1a, b
and Additional file 1: Figure S1), suggesting that
CYT997 exhibits inhibitory effects on cancer growth and
survival regardless of AR expression. DU145 and PC3
are highly invasive prostate cancer cells, and their inva-
sion potential was determined to explore the effect of
CYT997 on cell motility. Transwell invasion assays
showed that CYT997 effectively decreased cell invasion
(Fig. 1c), suggesting CYT997 may block metastasis of
prostate cancer. To determine the possible mechanisms
involved in mediating drug action, we examined multiple
oncogenic signaling pathways by Western blot. This in-
vestigation revealed a decreased phospho-activation of
AKT and ERK1/2 following CYT997 treatment (Fig. 1d),
which demonstrates that CYT997 can simultaneously
suppress PI3K/AKT and MAPK pathways. Phosphoryl-
ation of STAT3 in PC3 cells remained undetectable re-
gardless of CYT997 treatment; however, a sharp
decrease in activated STAT3 was observed in DU145
cells when exposed to CYT997 (Fig. 1d).
CYT997 induces apoptosis in prostate cancer cells
Our pervious study has shown that sorafenib and other
drugs approved for cancer treatment can cause mito-
chondrial dysfunction and increase intracellular oxida-
tive stress [28]. We next examined whether CYT997
affects oxidative stress on prostate cancer cells. The
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results from electrochemical biosensors showed that more
superoxide (O2
·−) were released in DU145 cells in the pres-
ence of CYT997 (Fig. 2a). In contrast, there was no differ-
ence in release of O2
·− with or without CYT997 treatment
(Fig. 2a). The cellular reactive oxygen species (ROS) evalu-
ated by DCFH-DA further showed a significant increase of
fluorescence in DU145 cells, but not in PC3 cells, following
CYT997 exposure (Fig. 2b). These results are very consistent
with the observations from electrochemical biosensors. To
study whether CYT997 induces cell apoptosis, we deter-
mined the levels of cleaved PARP with or without CYT997
treatment. CYT997 led to a remarkable increase in cleaved
PAPR in both DU145 and PC3 cells (Fig. 2c), which was
confirmed with an increased apoptotic rate (Fig. 2d). More-
over, either DU145 or PC3 cells did not render autophagy in
CYT997 treatment, as an evidence of no protein level
changes in autophagic flux markers LC3B-II and p62
(Fig. 2c), suggesting that CYT997 induces apoptosis in pros-
tate cancer cells via autophagy-independent mechanisms.
Inhibition of Src augments the cytotoxicity of CYT997 in
prostate cancer cells
As shown in Fig. 1d and Additional file 2: Figure S2,
phosphorylation levels of Src were increased in
CYT997-treated DU145 and PC3 cells compared with
non-treated control cells. These data prompted us to
investigate whether inhibition of Src expression im-
proves the CYT997 efficacy. We depleted Src in DU145
and PC3 cells using a shRNA strategy (Fig. 3a) and de-
termined the consequences of Src loss in the presence of
CYT997. Knockdown of Src not only inhibited cell pro-
liferation and invasion but also enhanced CYT997-
induced suppression on these phenotypes (Fig. 3b, c),
suggesting that blockage of Src may provide a clinical
benefit for cancer patients following CYT997 treatment.
Dasatinib, an orally bioavailable synthetic small mol-
ecule inhibitor, can bind to and inhibit the growth-
promoting activities of Src-family protein tyrosine ki-
nases [21]. We thus co-treated prostate cancer cells with
CYT997 and dasatinib. As would be expected, dasatinib
attenuated CYT997-mediated phospho-activation of Src,
with enhanced induction of cleaved PARP (Fig. 4a).
Moreover, the combination of CYT997 and dasatinib
acted more efficiently on cell death and apoptosis than
either of the drugs alone (Fig. 4b, c). Figure 4d demon-
strates that dasatinib augments the inhibitory effect of
CYT997 on cell invasion.
Dasatinib promotes the inhibitory effect of CYT997 on
growth of prostate tumor xenograft in vivo
Based on these encouraging data, we used mouse tumor
models to evaluate the synergistic effects of CYT997 and
Fig. 1 CYT997 exhibits potent cytotoxicity against prostate cancer cells in vitro. a, b 1 × 104 prostate cancer cells (DU145, PC3, LNCaP, and 22Rv1) were
seeded into 96-well plates and treated with the indicated concentrations of CYT997 for 48 h, and cell proliferation and viability were determined by
MTS assays (a) and CellTiter-Glo® Luminescent cell viability assays (b), respectively. c DU145 and PC3 cells were seeded into Matrigel-coated Boyden
chambers in the presence or absence of the indicated concentrations of CYT997 for 24 h, and invasion ability was quantitatively estimated by the
absorbance value. d DU145 and PC3 cells were treated with CYT997 for 24 h, and cell lysates were collected for Western blot with the
indicated antibodies
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dasatinib on prostate cancer. The metastatic PC3 cells
were implanted into the right flanks of NSG mice, and
drug administration commenced on day 4 after implant-
ation. Treatment with either CYT997 or dasatinib sig-
nificantly reduced the size and weight of PC3-derived
xenografts (Fig. 5a, b). The reduction in tumor
growth was more significant in the mice receiving
combined treatment compared with the mice receiv-
ing either drug alone (Fig. 5a, b). To determine
whether Src signaling is involved in the synergistic
Fig. 3 Knockdown of Src sensitizes prostate cancer cells to CYT997. a The shRNAs against Src (shSrc-1, shSrc-2) were used to deplete Src expression in
DU145 and PC3 cells. The shRNA against GFP (shGFP) was used as a negative control. After transfection and infection, the puromycin-resistant stable cells
were verified for knockdown by Western blot. b, c Src knockdown and control cells were treated with 60 nM CYT997. Cell proliferation was determined at
48 h after treatment by MTS assays (b), and cell invasion was determined at 24 h after treatment by Matrigel-coated modified Boyden chambers (c).
*p< 0.05; **p< 0.01
Fig. 2 CYT997 induces apoptosis but not autophagy in prostate cancer cells. a DU145 and PC3 cells were treated with 60 nM CYT997 for the
indicated times, and O2
·− release was determined by electrochemical biosensor. b DU145 and PC3 cells were treated with the indicated
concentrations of CYT997 for 8 h, and ROS generation was determined by DCFH-DA staining. c, d DU145 and PC3 cells were treated with the
indicated concentrations of CYT997 for 24 h, and cell lysates were collected for Western blot with the indicated antibodies (c), and apoptosis was
determined by Cell Death Detection Elisa kit (d). *p < 0.05; **p < 0.01
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Fig. 4 Dasatinib enhances in vitro cytotoxicity of CYT997 in prostate cancer cells. a DU145 and PC3 cells were treated with 60 nM CYT997 for
24 h, in the presence or absence of 50 nM dasatinib (Das). Cell lysates were collected for Western blot with the indicated antibodies. b–d PC3
cells were treated with 60 nM CYT997 for 24 h, in the presence or absence of 50 nM dasatinib. Cell death was determined by flow cytometry
with Zombie Aqua staining (b), apoptosis was determined by Cell Death Detection Elisa kit (c), and cell invasion was determined by Matrigel-
coated modified Boyden chambers (d). **p < 0.01
Fig. 5 Combination of CYT997 and dasatinib exhibits greater inhibitory activity of prostate tumor growth than either treatment alone. a, b When
the PC3-derived flank xenografts have been established, NSG mice were randomly divided into four groups (n = 5) for the indicated treatments.
Tumor growth was measured by tumor volume (a), and tumor burden at the end of the experiment was calculated as tumor weight (b). c, d
Mice were sacrificed on day 42 after treatment, and xenografts were dissected and removed for Western blot with the indicated antibodies (c)
and IHC with Ki67 antibody (d). In c, 1 and 2 indicate the tumor samples from two different mice. In d, representative images of IHC are shown in
the left panel, and quantitative data of staining intensity are shown in the right panel (n = 10). *p < 0.05; **p < 0.01
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drug effect, we examined Src activation using the cell ly-
sates collected from the xenografts treated with CYT997
and dasatinib, alone or in combination. Western blot ana-
lysis showed that phosphorylation levels of Src were re-
duced in the dasatinib arm, but not in the CYT997 arm
(Fig. 5c and Additional file 2: Figure S2). Dasatinib also
blocked Src activation in CYT997 treatment (Fig. 5c and
Additional file 2: Figure S2) and augmented CYT997-
induced repression of tumor growth. IHC analysis with a
Ki67 antibody confirmed that this co-treatment has a su-
perior inhibitory effect on prostate tumor growth com-
pared to monotherapy (Fig. 5d).
Combination of dasatinib and CYT997 strongly
suppresses prostate tumor metastasis in vivo
Our previous studies have demonstrated that tumor xeno-
grafts in NSG mice have potential to develop primary and
metastatic tumors coincidently [29]. Therefore, we
analyzed the mouse lungs and livers in xenograft
model on day 42 after treatment. Incidence of meta-
static nodules observed on the pulmonary and hep-
atic surface was significantly reduced in the mice
treated with CYT997 or dasatinib compared with the
mice treated with vehicle (Fig. 6a, c). The reduction
in metastases in drug treatment was confirmed by
histological analyses which showed decreased infil-
trating tumors throughout the entire lung and liver
(Fig. 6b, d). Combination of dasatinib and CYT997
displayed a stronger effect on suppression of metas-
tasis than monotherapy, as evidenced by reduced
nodule numbers on the pulmonary and hepatic sur-
face (Fig. 6a, c) and relatively few, small tumor foci
in the mice lung and liver (Fig. 6b, d). In order to
detect the drug efficacy in bone metastasis, we generated
Fig. 6 Dasatinib improves CYT997 efficacy in suppression of prostate cancer metastasis. a–d The tumor-bearing mice described in Fig. 5 were
sacrificed on day 42 after treatment, and the lungs and livers were dissected and removed. The metastatic nodules on the pulmonary or
hepatic surface were counted (a, c) (n = 5), and the tissue sections were stained with HE for pathological analysis (b, d). Black arrows in b indicate
tumor foci in the mice lung, and white stars in d indicate tumor foci in the mice liver. e NSG mice were injected via intracardiac with 1 × 106
luciferase-containing PC3 cells before treatment. Tumor progression was monitored by examining luminescence in Xenogen IVIS-200 In Vivo Imaging
System. *p < 0.05; **p < 0.01
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an experimental metastasis mouse model by intracardiac
injection of luciferase-containing PC3 cells. This model
allowed for determination of the process of metastatic
colonization at the bone and other organ sites followed by
bioluminescence imaging. Notably, PC3 cells established
colonies in the bone compartment of the hind leg (Fig. 6e).
In contrast to these observations, synergistic treatment al-
most completely blocked dissemination of PC3 cells to
other organs (Fig. 6e). These data suggest that dasatinib
would exert an additive anticancer effect with CYT997 in
treatment of patients with prostate cancer.
Discussion
Microtubules are essential for cell growth, division, mo-
tility, intracellular trafficking, and the ability to adapt to
a variety of shapes to interact with the environment [2].
Suppression of microtubule dynamics is a common
mechanism of chemotherapeutic agents to block mitosis
and kill tumor cells. CYT997, a novel anticancer MTA
with a favorable combination of pharmacologic and
pharmacokinetic properties and oral bioavailability, is
currently undergoing clinical trials in a variety of cancer
indications [9–11]. This work demonstrates the thera-
peutic efficacy of CYT997 in either cultured prostate
cancer cells or mouse models of prostate cancer and re-
veals the possible mechanisms involved in drug action.
The therapeutic goal of cancer treatment has been to
trigger tumor-selective cell death by apoptosis, and
drug-mediated autophagy is increasingly recognized as
an important factor in tumor apoptosis or survival [31].
Autophagic changes were not seen in the CYT997-
treated prostate cancer cells, excluding the possibility
that CYT997 promotes apoptosis in prostate cancer cells
by accumulation of autophagy. Oxidative stress is one of
the other contributing factors to apoptosis. CYT997 in-
duces an increase of ROS levels and O2
·− release in
DU145 cells, but not in PC3 cells. We also determined
oxidative stress in AR-positive LNCaP cells with or with-
out CYT997 treatment and observed the similar results
seen in PC3 cells (data not shown). This discrepancy
may be due to genetic background of the cell lines used
in our study. One of our follow-up investigations is to
discover possible molecular mechanisms mediating the
apoptotic effect of CYT997.
SRC kinase activity has been found to be upregulated in a
number of preclinical models of prostate cancer, and a po-
tentially effective strategy to inhibit prostate cancer growth
and metastasis is to target SRC kinases [21, 22]. Dasatinib in-
hibits multiple tyrosine kinases including SRC kinases, which
are implemented to promote androgen independence in
metastatic castration-resistant prostate cancer (mCRPC) that
makes malignant cells unresponsive to therapies [32, 33].
Some of the common chemo drugs used to treat prostate
cancer are MTAs. For example, docetaxel (Taxotere)
stabilizes microtubules through binding to polymerized
microtubules at the inner surface of the β subunit [34, 35].
As suggested by the phase III docetaxel plus dasatinib
study, combination treatment is most effective in delaying
and/or preventing skeletal metastases from prostate can-
cer [36]. However, no survival benefit was observed for
the addition of dasatinib to docetaxel versus docetaxel/
placebo [36, 37]. Despite the disappointing results seen
from studies evaluating dasatinib in combination with
other agents, clinical trials are needed to address whether
dasatinib may be used as a single agent or in combination
with chemotherapy mediated by novel MTAs.
There is a clear potential for CYT997 to be used in all
prostate tumors carrying AR or not and perhaps all clinical
stages of prostate cancer since it can greatly inhibit nearly
all prostate cancer cell lines. Our data indicate that
CYT997 possess highly potent cytotoxic activity through
inhibiting the PI3K/AKT and MAPK oncogenic signaling
cascades. However, CYT997 cannot block the Src pathway
at the examined concentrations. Considering that mono-
therapy frequently fails to produce an adequate response
and combining cancer drugs with disparate mechanisms of
action is a feasible strategy to achieve high anticancer activ-
ities, we treated prostate cancer cells with CYT997 and
dasatinib. This drug combination shows synergistically de-
creased cell proliferation and increased apoptosis, leading
to distinctly improved anticancer activities in vitro and in
vivo. In the present study, we generated two types of pros-
tate cancer mouse models using PC3 cells. The combin-
ation of CYT997 and dasatinib inhibits both prostate
tumor growth and metastasis in these mouse models, pro-
viding a rational basis for the clinical treatment for patients
with prostate cancer. Since the majority of mCRPC con-
tains AR or even overexpresses it, use of different cells such
as C4-2B (a cell line can produce osteoblastic metastases in
the lumbar spine) would provide another model to explore
the mechanisms of drug action and add value to the ob-
tained findings. Future trials should identify patient sub-
populations with elevated activation of Src in prostate
cancer and better define the biologic processes of prostate
cancer progression that are specifically “Src-driven.” Com-
bination treatment of CYT997 and dasatinib may be devel-
oped as a novel therapy to improve clinical outcomes for
prostate cancer carrying high levels of activated Src.
Conclusions
Taking the obtained findings together, this work
shows for the first time that blockage of Src by
dasatinib can augment the anticancer efficacy of
CYT997 in prostate cancer development and pro-
gression. Our study explicates a rational basis of
synergistic actions of CYT997 and dasatinib and pro-
vides preclinical data for possible clinical application
of this novel therapeutic strategy. In future work, we
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will improve drug delivery system to target prostate
cancer more effectively and precisely.
Additional files
Additional file 1: Figure S1. CYT997 inhibits proliferation (a) and
viability (b) of LNCaP derivative prostate cancer cell lines C4-2 and C4-2B.
*p < 0.05; **p < 0.01. (DOCX 132 kb)
Additional file 2: Figure S2. Quantitative data of phosphorylation Src
levels in in vitro (a, representative images are shown in Fig. 1d) or in vivo
treatment (b, representative images are shown in Fig. 5c). *p< 0.05; **p< 0.01;
n= 5. (DOCX 127 kb)
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